DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Singapore ONLY.

Information about the NuvaxovidTM dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)

The Health Sciences Authority (HSA) of Singapore has authorized the interim authorization of the NuvaxovidTM dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) under Regulations 60A(4) and (5)b of the Health Product (Therapeutic Products) Regulations, for use and supply as directed by the Government of Singapore. Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Report an Adverse Event (AE)

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Singapore: https://www.hsa.gov.sg/adverse-events.

Contact Us

Tel: +65 8003211411
09:00 - 17:00
Monday - Friday